Locate Bio to be Granted Key US and EU Patents for its Gene Delivery Tech

January 17, 2019

Cell and gene therapy platform company, Locate Bio, has announced that it is set to receive key patents for its IntraStem technology covering the United States and Europe

Cell and gene therapy platform company, Locate Bio, has announced that it is set to receive key patents for its IntraStem technology covering the United States and Europe, in a Jan. 7, 2019 press release.

IntraStem is a non-viral gene delivery technology that is based on cell penetrating peptides. The intracellular delivery system has been designed to overcome the limitations of current gene therapy vectors. Additionally, as a next-generation approach, the system is capable of delivering a variety of biologics, such as plasmid DNA, mRNA, siRNA, proteins, and antibodies, in various cell types, including hard-to-transfect cells.

“The granting of our first IntraStem patents in the US and Europe adds to the excitement building around our next generation, non-viral transfection technology,” commented Nick Staples, CEO of Locate, in a Jan. 7, 2019 press release. “We are delighted with the comparative performance of IntraStem versus current transfection standards, which has now extended across a wide range of cell types, payloads, and preclinical models. The broad utility of IntraStem opens up a multitude of therapeutic opportunities, including gene editing and cell reprogramming in-vivo. We are presently evaluating new product opportunities in therapy areas where cell and gene therapies may deliver breakthrough and potentially curative benefits to patients."

Source: Locate Bio